Clinical Trial Results:
Clinical trial Phase I/II, test of concept, double blind, randomized, controlled with placebo, to evalue the safety and efficiency of the treatment with expanded adult mesenchymal stem cells from allogenic adipose tissue, in patients with HIV infection with controlled viral load and immunological discordant response.
Summary
|
|
EudraCT number |
2014-000307-26 |
Trial protocol |
ES |
Global end of trial date |
30 Jul 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
14 Feb 2024
|
First version publication date |
14 Feb 2024
|
Other versions |
|
Summary report(s) |
CeTMAd-VIH-2014 CeTMAd-VIH-2014 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CeTMAd-VIH-2014
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Fundación Pública Andaluza Progreso y Salud M. P.
|
||
Sponsor organisation address |
Avda. Américo Vespucio 15 · Edificio S-2 ·2ª Pta., Sevilla, Spain, Sevilla, Spain,
|
||
Public contact |
Ana Cardesa Gil, Iniciativa Andaluza en Terapias Avanzadas-Fundación Pública Andaluza Progreso y Salud, +34 NA955048366NA, ana.cardesa@juntadeandalucia.es
|
||
Scientific contact |
Ana Cardesa Gil, Iniciativa Andaluza en Terapias Avanzadas-Fundación Pública Andaluza Progreso y Salud, +34 NA955048366NA, ana.cardesa@juntadeandalucia.es
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
27 Jul 2022
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
30 Jun 2019
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
30 Jul 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
1. To evaluate the safety of the intravenous infusion of 4 doses of allogenic mesenchimal stem cells from adipose tissue (ASC), in patients with infection for HIV and immunological discordant response.
2. To evaluate the efficiency of the intravenous infusion of 4 ASC's doses in the immunological recovery after 3 monthly cycles of CeTMAd's infusion and 1 additional infusion in week 20 in patients with infection for HIV and immunological discordant response.
|
||
Protection of trial subjects |
The trial has been carried out in accordance with the recommendations for Clinical Trials and the evaluation of the product under investigation in humans, which appear in the Declaration of Helsinki,
revised in successive world assemblies (WMA, 2008), and the current Spanish Legislation on Clinical Trials. In addition, the ICH-GPC standards have been followed.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jun 2016
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 5
|
||
Worldwide total number of subjects |
5
|
||
EEA total number of subjects |
5
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
5
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||
Recruitment
|
|||||||
Recruitment details |
- | ||||||
Pre-assignment
|
|||||||
Screening details |
- | ||||||
Pre-assignment period milestones
|
|||||||
Number of subjects started |
5 | ||||||
Number of subjects completed |
5 | ||||||
Period 1
|
|||||||
Period 1 title |
Recruitment and follow-up (overall period)
|
||||||
Is this the baseline period? |
Yes | ||||||
Allocation method |
Non-randomised - controlled
|
||||||
Blinding used |
Not blinded | ||||||
Arms
|
|||||||
Arm title
|
Group A | ||||||
Arm description |
- | ||||||
Arm type |
Experimental | ||||||
Investigational medicinal product name |
CeTMAd
|
||||||
Investigational medicinal product code |
|||||||
Other name |
|||||||
Pharmaceutical forms |
Suspension for injection in pre-filled syringe
|
||||||
Routes of administration |
Intraarterial use
|
||||||
Dosage and administration details |
0.5x106 células / kg peso paciente.
|
||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Group A
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Group A
|
||
Reporting group description |
- | ||
Subject analysis set title |
Feasibility and safety
|
||
Subject analysis set type |
Full analysis | ||
Subject analysis set description |
Feasibility and safety
|
|
||||||||||
End point title |
Safety [1] | |||||||||
End point description |
||||||||||
End point type |
Primary
|
|||||||||
End point timeframe |
During the study
|
|||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Information included in summary |
||||||||||
|
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||
Adverse events information
|
|||||||||||||||
Timeframe for reporting adverse events |
From the inclusion of the first patient to the last visit of the last patient.
|
||||||||||||||
Assessment type |
Systematic | ||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||
Dictionary version |
NA
|
||||||||||||||
Reporting groups
|
|||||||||||||||
Reporting group title |
Group 1
|
||||||||||||||
Reporting group description |
- | ||||||||||||||
|
|||||||||||||||
Frequency threshold for reporting non-serious adverse events: 0% | |||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
19 Sep 2016 |
The use of premedication is considered before each CetMAd infusion. Update of co-investigators and inclusion of the UPCIT of the CHUGr as the center involved in the trial.
Update of the scale for the gradation of AAs (DAIDs table), of the clinical trial schedule repealed regulations (EECC, donation of tissues and TAs), and of the methods accepted contraceptives. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |